BKM120 addition to BI-3406 and trametinib combination yields minimal pancreatic cancer benefit but significant adverse effects
Background
Achieving effective and tolerable combinatorial therapies for pancreatic cancer remains a critical challenge. Despite advances, traditional treatments often face drug resistance and significant side effects. This study addresses the need to balance efficacy and toxicity in new regimens, specifically exploring the impact of targeting the PI3K pathway with BKM120 alongside a dual KRAS/SOS1 inhibitor (BI-3406) and a MEK inhibitor (trametinib), given the frequent dysregulation of these pathways in pancreatic malignancies.
Study Design
Researchers evaluated the therapeutic effects of BKM120 added to BI-3406 and trametinib in pancreatic cancer cell line 6606PDA using both monolayer and three-dimensional cultures. For in vivo assessment, a syngeneic orthotopic mouse model of pancreatic cancer was employed. The study compared the triple therapy group against a dual therapy group (BI-3406 plus trametinib). Primary endpoints included cell viability, survival outcome, tumor weights, cancer cell proliferation, Cdkn2a and PD-L1 expression, CD8+ T-cell infiltration, lung metastases, blood cell counts, C-peptide levels, and behavioral analysis (burrowing/nesting activities).
Results
In vitro, adding BKM120 to BI-3406 and trametinib significantly reduced cell viability in both monolayer and three-dimensional cultures. However, in the syngeneic pancreatic cancer mouse model, the triple therapy failed to significantly improve survival outcome compared to the dual therapy. Tumor weights were unaffected in female mice, while a minor, non-significant reduction was observed in male mice, accompanied by a slight, non-significant decrease in cancer cell proliferation. Cdkn2a expression in tumors remained largely unchanged. > Crucially, the triple therapy significantly increased lung metastases in female mice, reduced lymphocyte and erythrocyte counts, and elevated C-peptide concentrations in both sexes. PD-L1 was significantly reduced in males, and CD8+ T-cell infiltration was notably enhanced in females. Behavioral analysis showed a significant decline in burrowing and nesting activities among female mice during specific experimental phases.
Key Findings
- Triple therapy with BKM120, BI-3406, and trametinib significantly reduced cell viability in vitro.
- Triple therapy failed to significantly improve survival outcome in a syngeneic mouse model.
- Triple therapy significantly increased lung metastases in female mice.
- Triple therapy reduced lymphocyte and erythrocyte counts, and elevated C-peptide in both sexes.
- PD-L1 was significantly reduced in male mice, and CD8+ T-cell infiltration enhanced in female mice.
Why It Matters
This study provides a critical cautionary tale for combination cancer therapies, particularly when integrating PI3K inhibitors. The findings underscore that in vitro synergy does not always translate to in vivo benefit, and can even introduce severe adverse effects. For those considering multi-drug protocols, this research highlights the complex interplay of pathways and the potential for unexpected toxicities, such as increased metastasis and metabolic dysfunction, even when targeting established oncogenic drivers like KRAS and PI3K. It emphasizes the need for rigorous preclinical validation of combination regimens before clinical translation, especially when balancing efficacy with systemic safety.
pancreatic cancer
combination therapy
pi3k inhibitor
kras inhibitor
mek inhibitor
bkm120